Table 1 Clinical characteristics of the study population
From: Validation of the Hungarian version of the SRI Questionnaire
COPD | RCWD | OHS/OSAS | NMD | Total | |
|---|---|---|---|---|---|
n (%) | 20(19.2%) | 6(5.8%) | 45(43.3%) | 31(29.8%) | 104(100%) |
Age (yr) | 66.0(±6.8) | 36.5 ± 13.0) | 57.3(±13.3) | 46.7(±18.8) | 54.5(±16.2) |
Male (%) | 15(75%) | 1(8.3%) | 35(77.8%) | 7(88.4%) | 77(74.0%) |
BMI (kg/m2) | 33.9(±7.4) | 19.4(±3.4) | 41.2(±10.8) | 24.1(±4.4) | 33.1(±11.6) |
Smoking (packyear) | 26.7(±29.6) | 7.5(±17.9) | 16.8(±22.3) | 6.3(±16.9) | 14.7(±23.1) |
HMV (hr/d) | 8.0(±2.0) | 10.7(±6.4) | 6.4(±1.7) | 12.4(±5.7) | 9.0(±4.8) |
HMV (mo) | 28.1(±29.6) | 27.5(±39.6) | 30.6(±37.2) | 19.7(±26.8) | 26.2(±32.7) |
O2 need | 14(70%) | 4(6%) | 19(42.2%) | 7(22.6%) | 46(44.2%) |
FVC% | 71.2(±23.6) | 23.8(±12.5) | 80.9 ± 19.6 | 36.1(±19.5 | 68.3(±28.9) |
FEV1% | 44.7(23.6) | 23.8(±12.5) | 72.5(±20.6) | 36.4(±22.1) | 53.3(±27.5) |
FEV1/FVC% | 63.0(±20.6) | 86.3(±17.8) | 92.2(±13.7) | 100.5(±17.8) | 88.0(±21.4) |
PEF% | 44.7(±23.7) | 28.8(±16.3) | 71.2(±24.4) | 31.6(±21.0) | 51.6(±28.9) |
pH | 7.40(±0.05) | 7.38(±0.03) | 7.41(±0.04) | 7.40(±0.04) | 7.40(±0.04) |
pCO2 (mmHg) | 44.8(±10.4) | 43.8(±9.4) | 42.3(±9.6) | 41.4(±8.8) | 42.6(±9.5) |
pO2 (mmHg) | 70.2(±15.6) | 84.0(±10.3) | 73.3(±10.4) | 87.0(±10.6) | 77.5(±13.3) |
IPAP (cmH2O) | 17.9(±3.3) | 22.0(±3.2) | 19.3(±4.7) | 18.5(±3.9) | 18.9(±4.1) |
EPAP (cmH2O) | 7.8(±2.9) | 6.7(±2.9) | 9.6(±3.1) | 7.6(±3.4) | 8.4(±3.3) |
PTB (%) | 62.7(±34.2) | 25.5(±25.4) | 65.5(±32.0) | 45.9(±28.3) | 57.0(±32.5) |
VTE (mL) | 669.1(±155.9) | 367.9(±62.5) | 648.3(±245.2) | 483.6(±94.4) | 585.5(±205.1) |
Ti/Tt | 31.7(±5.6) | 32.0(±7.4) | 36.4(±5.4) | 32.1(±5.5) | 33.8(±5.9) |